News

Porcupine inhibition represents a promising treatment for sclerosteosis patients
New research from the Royal Veterinary College (RVC) has identified porcupine inhibition—a strategy that blocks a key ...
C&EN16d
HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, ...
Frontiers22d
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment
Our study examines factors influencing Janus kinase (JAK) inhibitor effectiveness by analyzing interindividual variability in demographic and clinical characteristics of real-world RA patients.
C&EN23d
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States ...
FierceBiotech25d
Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan
Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...
SiliconRepublic25d
UCD epilepsy researcher is developing targeted interventions
If inhibition of demethylase enzyme proves effective in both animal models and human tissue, it could offer a groundbreaking approach to epilepsy management, bringing new hope to millions affected ...